16019-34-4

Upstream product

• 100-39-0 benzyl bromide 
• 3680-69-1 4-chloro-1H-pyrrolo[2,3-d]pyrimidine 
• 186519-89-1 7-(benzenesulfonyl)-4-chloro-7H-pyrrolo[2,3-d]pyrimidine 
• 100-51-6 benzyl alcohol 
• 100-44-7 benzyl chloride 

Downstream Products

• 1143505-19-4 7-benzyl-4-chloro-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-7H-pyrrolo[2,3-d]pyrimidine 
• 1143505-16-1 7-benzyl-4-phenyl-7H-pyrrolo[2, 3-d]pyrimidine 
• 1398560-69-4 C₁₉H₁₆N₄O 
• 1448695-63-3 7-benzyl-4-phenyl-5-(phenylsulfanyl)-7H-pyrrolo[2,3-d]pyrimidine 

Relevant academic research and scientific papers

4,7-disubstituted 7h-pyrrolo[2,3-d]pyrimidines and their analogs as antiviral agents against zika virus

Discovery of compound 1 as a Zika virus (ZIKV) inhibitor has prompted us to investigate its 7H-pyrrolo[2,3-d]pyrimidine scaffold, revealing structural features that elicit antiviral activity. Furthermore, we have demonstrated that 9H-purine or 1H-pyrazolo[3,4-d]pyrimidine can serve as an alternative core structure. Overall, we have identified 4,7-disubstituted 7H-pyrrolo[2,3-d]pyrimidines and their analogs including compounds 1, 8 and 11 as promising antiviral agents against flaviviruses ZIKV and dengue virus (DENV). While the molecular target of these compounds is yet to be elucidated, 4,7-disubstituted 7H-pyrrolo[2,3-d]pyrimidines and their analogs are new chemotypes in the design of small molecules against flaviviruses, an important group of human pathogens.

Synthesis method of tofacitinib key intermediate

The invention relates to a method for preparing high-purity (N-methyl N ((3R, 4R)-4-methylpiperidine-3-yl)-7H-pyrrolo [2, 3-d] pyrimidine-4-amine (tofacitinib key intermediate). According to the method, 4-chloro-7H-pyrrolo [2, 3-d] pyrimidine is taken as an initial raw material, benzyl protection, condensation reaction and dibenzyl protection removal reaction are carried out, and then purification is carried out, so that the product disclosed by the invention is obtained. The purity of the product (N-methyl N ((3R, 4R)-4-methylpiperidine-3-yl)-7H-pyrrolo [2, 3-d] pyrimidine-4-amine is 98% orabove; the total yield of the synthesis method is 80% or above; and the synthesis method is suitable for industrial production.

Novel drug-like somatostatin receptor 4 agonists are potential analgesics for neuropathic pain

Somatostatin released from the capsaicin-sensitive sensory nerves mediates analgesic and anti-inflammatory effects via the somatostatin sst4 receptor without endocrine actions. Therefore, sst4 is considered to be a novel target for d

Identification and synthesis of substituted pyrrolo[2,3-d]pyrimidines as novel firefly luciferase inhibitors

A novel firefly luciferase inhibitor (3a) with a pyrrolo[2,3-d]pyrimidine core was identified in a cell-based NF-κB luciferase reporter gene assay. It potently inhibited the firefly luciferase derived from Photinus pyralis with an IC50 value of 0.36 ± 0.05 μM. Kinetic analysis of 3a inhibition showed that it is predominantly competitive with respect to d-luciferin and uncompetitive with respect to ATP. Therefore, several pyrrolo[2,3-d]pyrimidine analogues were prepared to further investigate the structure-activity relationship (SAR) for luciferase inhibition. The most potent inhibitor of this series was 4c, which showed an IC50 value of 0.06 ± 0.01 μM. In addition, molecular docking studies suggested that both 3a and 4c could be accommodated in the d-luciferin binding pocket, which is expected for a predominantly competitive inhibitor with respect to d-luciferin.

Pyrrolo[2,3-d]pyrimidine compounds

A compound of the formula wherein R1, R2 and R3 are as defined above, which are inhibitors of the enzyme protein tyrosine kinases such as Janus Kinase 3 and as such are useful therapy as immunosuppressive agents for organ transplants, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, Leukemia and other autoimmune diseases.

Selective N-alkylation of pyrrolopyrimidines and indoles by 'transfer of activation'

The benzene sulfonyl group is used as a 'transfer of activation' reagent to alkylate selectively the NH of both pyrrolopyrimidines and 5-aminoindoles substituted on thienopyrimidines. A variety of primary and secondary alcohols are utilized as alkylating

Synthesis and anticonvulsant activity of N-benzylpyrrolo[2,3-d]-, - pyrazolo[3,4-d]-, and -triazolo[4,5-d]pyrimidines: Imidazole ring-modified analogues of 9-(2-fluorobenzyl)-6-(methylamino)-9H-purine

Analogues of 9-(2-fluorobenzyl)-6-(methylamino)-9H-purine (1) containing isosteric replacements of the imidazole ring atoms were synthesized and tested for anticonvulsant activity. The pyrrolo[2,3-d]-, pyrazolo[a,4-d]-, and triazolo[4,5-d]pyrimidines were less active than 1 against maximal electroshock-induced seizures (MES) in rats when given po. The differences in anti-MES activity for these analogues was not explained by differences in pK(a) or lipophilicity. However, the four classes of heterocycles have distinctly different calculated electrostatic isopotential maps, which may be related to optimum anticonvulsant activity.